Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for sgen
27.04
+0.17 (0.63%)
After Hours: 26.98 -0.06 (-0.22%)
Feb 11, 4:42PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.11 - 27.70
52 week 26.02 - 52.33
Open 26.14
Vol / Avg. 2.14M/1.49M
Mkt cap 3.49B
P/E     -
Div/yield     -
EPS -0.94
Shares 139.46M
Beta 1.55
Inst. own 104%
Apr 28, 2016
Q1 2016 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 11, 2016
Seattle Genetics Inc at Leerink Partners Global Healthcare Conference
Feb 9, 2016
Q4 2015 Seattle Genetics Inc Earnings Call - Webcast
Feb 9, 2016
Q4 2015 Seattle Genetics Inc Earnings Release
Jan 11, 2016
Seattle Genetics Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 11, 2016
Seattle Genetics Inc at JPMorgan Healthcare Conference
Dec 9, 2015
Seattle Genetics Inc at Oppenheimer Healthcare Conference - Webcast
Dec 7, 2015
Seattle Genetics Inc Investor and Analyst Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -26.59% -35.77%
Operating margin -26.90% -35.91%
EBITD margin - -35.91%
Return on average assets -11.06% -17.80%
Return on average equity -14.43% -26.87%
Employees 657 -
CDP Score - -

Address

21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Company's pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics' sugar-engineered antibody (SEA) technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Todd E Simpson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 53
Bio & Compensation  - Reuters
Vaughn B. Himes Executive Vice President - Technical Operations, Process Sciences
Age: 54
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 46
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters